moneyheap
PEN · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Penumbra, Inc. (PEN) stock moving?
Penumbra's main headline is the pending $14.5 billion acquisition by Boston Scientific, whose closing was pushed to Q1 2027 on regulatory delays. Q3 2026 sales of $410.1 million beat the $403.3 million estimate, but EPS of $1.07 missed the $1.25 estimate. The stock has traded in a tight range of roughly $316 to $326 over the last 15 sessions and closed at $321.46 on Nov 10, about 1.1% below the $324.96 close on Oct 22. Volume peaked at 851K shares on Oct 28, just before the Oct 29 results and deal-delay news, and has since faded to 242K on Nov 10, the lowest level in the window. The steady price and fading volume are consistent with a stock anchored to a pending deal, but the offer price is not in the provided data, so the upside and downside cannot be quantified. The delay adds timing risk without any reported change to the deal terms.
News behind the analysis
- Penumbra, Inc. Reports Third Quarter 2026 Financial ResultsPenumbra reported Q3 2026 revenue of $410.1 million and net income of $42.3 million.
- Penumbra Q3 EPS $1.07 Misses $1.25 Estimate, Sales $410.145M Beat $403.345M EstimateQ3 EPS of $1.07 missed the $1.25 estimate, while sales of $410.145M beat the $403.345M estimate.
- Boston Scientific Delays Penumbra Acquisition Closing to Q1 2027Boston Scientific's $14.5 billion acquisition of Penumbra is now expected to close in Q1 2027 because of regulatory delays.
About Penumbra, Inc.
Penumbra is a medical device company based in Alameda, California, and calls itself the world's leading thrombectomy company. It makes catheter-based systems that remove blood clots from the brain, lungs and limbs, and Boston Scientific has agreed to buy it, with the deal still pending in 2026.
How it makes money
Penumbra makes its money selling single-use devices to hospitals. Thrombectomy products, including computer-assisted clot-removal systems used for stroke and venous clots (VTE, meaning clots in the veins), bring in roughly two-thirds of revenue. Embolization and access products, such as coils, catheters and other tools for blocking blood vessels or reaching them, make up the other third or so. About three-quarters of sales come from the US. Revenue was about $1.4 billion in 2025, and quarterly revenue was about $410 million in Q3 2026, up roughly 16% from a year earlier.
What usually moves PEN
- Progress and closing of the pending Boston Scientific acquisition
- Growth in US clot-removal procedures for VTE and stroke
- Clinical trial results and new product launches
- Hospital spending and procedure volumes
- Sales trends in China and other international markets